Publications
Our peer-reviewed literature and conference publications are available to read in this section
All of our product candidates are investigational, meaning they are not yet approved for treatment of any of the diseases being studied.
Infectious Disease Focus Areas
Date Range
Explore
Search
C. difficile infection / 13 Jul 2020
Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids
X. Qian Et Al: American Journal of Physiology, Gastrointestinal and Liver Physiology
C. difficile infection / 07 Oct 2019
Effect of broad vs. narrow spectrum Clostridioides difficile treatment on human stool bile acid composition over time
X. Qian Et Al: ID Week 2019
C. difficile infection / 07 Oct 2019
Narrow-spectrum antibiotic treatment of Clostridium difficile infection improves preservation of intestinal metabolic profile
K. Yanagi Et Al: ID Week 2019
C. difficile infection / 03 Oct 2019
Quality of Life Changes in Patients with Clostridium difficile Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared to Vancomycin (VAN)
S. Paul Et Al: ID Week 2019
/ 18 Sep 2019
Combating resistance while maintaining innovation: the future of antimicrobial stewardship
R. Vickers Et Al: Future Microbiology
Enterobacteriaceae / 05 Sep 2019
In vivo Proof of Concept for a Novel Small Molecule Inhibitor of Bacterial Lipoprotein Transport Targeting Enterobacteriaceae
E. Breidenstein Et Al: ASM/ESCMID
Gonorrhoea / 17 Jul 2019
In Vitro Activity of SMT-571 & Comparators Against Clinical Isolates & Reference Strains of Neisseria gonorrhoeae
S. Jacobsson Et Al: STI & HIV World Congress
Gonorrhoea / 24 Jun 2019
In Vitro Activity of SMT-571 & Comparators Against Clinical Isolates & Reference Strains of Neisseria gonorrhoeae
S. Jacobsson Et Al: ASM Microbe 2019
C. difficile infection / 24 Jun 2019
ASM Hub Track: Pharma Pipeline
Et Al: ASM Microbe 2019
Enterobacteriaceae / 14 Apr 2019
Novel Small-Molecule Inhibitors of Bacterial Lipoprotein Transport with Potent Antimicrobial Activity Against Enterobacteriaceae
E. Breidenstein Et Al: ECCMID 2019
Gonorrhoea / 25 Feb 2019
In vitro activity of the novel oral antimicrobial SMT-571, with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae: future treatment option for gonorrhoea?
S. Jacobsson Et Al: J. Antimicrobial Chemotherapy
Gonorrhoea / 13 Nov 2018
A Novel Small Molecule Antibiotic for the Treatment of Neisseria gonorrhoeae
Et Al: SCI/RSC Symposium on Antimicrobial Drug Discovery